Topics

Novo Nordisk set to launch price cut for insulin drug NovoLog after harsh criticism over prices in the US

09:16 EDT 9 Sep 2019 | Pharmafile

Danish drug maker Novo Nordisk has said it will offer a generic version of NovoLog (insulin aspart) at a price of $145 per vial, nearly half of the branded drug’s currently listed price. The price cut will come into effect from January 2020.

The company will also launch a cash card programme next year which will lead to patients with or without insurance being able to purchase its older analogue insulin products in vial or pen formats for just $99.

read more

Original Article: Novo Nordisk set to launch price cut for insulin drug NovoLog after harsh criticism over prices in the US

NEXT ARTICLE

More From BioPortfolio on "Novo Nordisk set to launch price cut for insulin drug NovoLog after harsh criticism over prices in the US"

Quick Search

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...